120 related articles for article (PubMed ID: 31705877)
1. The Identification of Potential Therapeutic Targets for Cutaneous Squamous Cell Carcinoma.
McHugh A; Fernandes K; Chinner N; Ibrahim AFM; Garg AK; Boag G; Hepburn LA; Proby CM; Leigh IM; Saville MK
J Invest Dermatol; 2020 Jun; 140(6):1154-1165.e5. PubMed ID: 31705877
[TBL] [Abstract][Full Text] [Related]
2. Inactivation of the CRL4-CDT2-SET8/p21 ubiquitylation and degradation axis underlies the therapeutic efficacy of pevonedistat in melanoma.
Benamar M; Guessous F; Du K; Corbett P; Obeid J; Gioeli D; Slingluff CL; Abbas T
EBioMedicine; 2016 Aug; 10():85-100. PubMed ID: 27333051
[TBL] [Abstract][Full Text] [Related]
3. Ubiquitin E3 ligase CRL4(CDT2/DCAF2) as a potential chemotherapeutic target for ovarian surface epithelial cancer.
Pan WW; Zhou JJ; Yu C; Xu Y; Guo LJ; Zhang HY; Zhou D; Song FZ; Fan HY
J Biol Chem; 2013 Oct; 288(41):29680-91. PubMed ID: 23995842
[TBL] [Abstract][Full Text] [Related]
4. High Expression of Ubiquitin-Specific Protease 8 (USP8) Is Associated with Poor Prognosis in Patients with Cervical Squamous Cell Carcinoma.
Yan M; Zhao C; Wei N; Wu X; Cui J; Xing Y
Med Sci Monit; 2018 Jul; 24():4934-4943. PubMed ID: 30010158
[TBL] [Abstract][Full Text] [Related]
5. The NAE inhibitor pevonedistat interacts with the HDAC inhibitor belinostat to target AML cells by disrupting the DDR.
Zhou L; Chen S; Zhang Y; Kmieciak M; Leng Y; Li L; Lin H; Rizzo KA; Dumur CI; Ferreira-Gonzalez A; Rahmani M; Povirk L; Chalasani S; Berger AJ; Dai Y; Grant S
Blood; 2016 May; 127(18):2219-30. PubMed ID: 26851293
[TBL] [Abstract][Full Text] [Related]
6. Neddylation inhibitor MLN4924 suppresses growth and migration of human gastric cancer cells.
Lan H; Tang Z; Jin H; Sun Y
Sci Rep; 2016 Apr; 6():24218. PubMed ID: 27063292
[TBL] [Abstract][Full Text] [Related]
7. Suppression of autophagy during mitosis via CUL4-RING ubiquitin ligases-mediated WIPI2 polyubiquitination and proteasomal degradation.
Lu G; Yi J; Gubas A; Wang YT; Wu Y; Ren Y; Wu M; Shi Y; Ouyang C; Tan HWS; Wang T; Wang L; Yang ND; Deng S; Xia D; Chen RH; Tooze SA; Shen HM
Autophagy; 2019 Nov; 15(11):1917-1934. PubMed ID: 30898011
[TBL] [Abstract][Full Text] [Related]
8. The Neddylation Inhibitor Pevonedistat (MLN4924) Suppresses and Radiosensitizes Head and Neck Squamous Carcinoma Cells and Tumors.
Vanderdys V; Allak A; Guessous F; Benamar M; Read PW; Jameson MJ; Abbas T
Mol Cancer Ther; 2018 Feb; 17(2):368-380. PubMed ID: 28838998
[TBL] [Abstract][Full Text] [Related]
9. Quantitative proteomic analysis of cellular protein modulation upon inhibition of the NEDD8-activating enzyme by MLN4924.
Liao H; Liu XJ; Blank JL; Bouck DC; Bernard H; Garcia K; Lightcap ES
Mol Cell Proteomics; 2011 Nov; 10(11):M111.009183. PubMed ID: 21873567
[TBL] [Abstract][Full Text] [Related]
10. Targeting the protein ubiquitination machinery in melanoma by the NEDD8-activating enzyme inhibitor pevonedistat (MLN4924).
Wong KM; Micel LN; Selby HM; Tan AC; Pitts TM; Bagby SM; Spreafico A; Klauck PJ; Blakemore SJ; Smith PF; McDonald A; Berger A; Tentler JJ; Eckhardt SG
Invest New Drugs; 2017 Feb; 35(1):11-25. PubMed ID: 27783255
[TBL] [Abstract][Full Text] [Related]
11. WEE1 accumulation and deregulation of S-phase proteins mediate MLN4924 potent inhibitory effect on Ewing sarcoma cells.
Mackintosh C; García-Domínguez DJ; Ordóñez JL; Ginel-Picardo A; Smith PG; Sacristán MP; de Álava E
Oncogene; 2013 Mar; 32(11):1441-51. PubMed ID: 22641220
[TBL] [Abstract][Full Text] [Related]
12. Protein neddylation and its alterations in human cancers for targeted therapy.
Zhou L; Zhang W; Sun Y; Jia L
Cell Signal; 2018 Apr; 44():92-102. PubMed ID: 29331584
[TBL] [Abstract][Full Text] [Related]
13. Discovery of Potent OTUB1/USP8 Dual Inhibitors Targeting Proteostasis in Non-Small-Cell Lung Cancer.
Tan L; Shan H; Han C; Zhang Z; Shen J; Zhang X; Xiang H; Lu K; Qi C; Li Y; Zhuang G; Chen G; Tan L
J Med Chem; 2022 Oct; 65(20):13645-13659. PubMed ID: 36221183
[TBL] [Abstract][Full Text] [Related]
14. A first-in-class inhibitor, MLN4924 (pevonedistat), induces cell-cycle arrest, senescence, and apoptosis in human renal cell carcinoma by suppressing UBE2M-dependent neddylation modification.
Xu B; Deng Y; Bi R; Guo H; Shu C; Shah NK; Chang J; Liu G; Du Y; Wei W; Wang C
Cancer Chemother Pharmacol; 2018 Jun; 81(6):1083-1093. PubMed ID: 29667067
[TBL] [Abstract][Full Text] [Related]
15. The oncogenic role of ubiquitin specific peptidase (USP8) and its signaling pathways targeting for cancer therapeutics.
Islam MT; Chen F; Chen H
Arch Biochem Biophys; 2021 Apr; 701():108811. PubMed ID: 33600786
[TBL] [Abstract][Full Text] [Related]
16. Selective enhancing effect of early mitotic inhibitor 1 (Emi1) depletion on the sensitivity of doxorubicin or X-ray treatment in human cancer cells.
Shimizu N; Nakajima NI; Tsunematsu T; Ogawa I; Kawai H; Hirayama R; Fujimori A; Yamada A; Okayasu R; Ishimaru N; Takata T; Kudo Y
J Biol Chem; 2013 Jun; 288(24):17238-52. PubMed ID: 23645673
[TBL] [Abstract][Full Text] [Related]
17. Proteomics identifies neddylation as a potential therapy target in small intestinal neuroendocrine tumors.
Fotouhi O; Kjellin H; Juhlin CC; Pan Y; Vesterlund M; Ghaderi M; Yousef A; Andersson-Sand H; Kharaziha P; Caramuta S; Kjellman M; Zedenius J; Larsson C; Orre LM
Oncogene; 2019 Oct; 38(43):6881-6897. PubMed ID: 31406256
[TBL] [Abstract][Full Text] [Related]
18. Early mitotic inhibitor-1, an anaphase-promoting complex/cyclosome inhibitor, can control tumor cell proliferation in hepatocellular carcinoma: correlation with Skp2 stability and degradation of p27(Kip1).
Zhao Y; Tang Q; Ni R; Huang X; Wang Y; Lu C; Shen A; Wang Y; Li C; Yuan Q; Chen H; Cheng C; He S
Hum Pathol; 2013 Mar; 44(3):365-73. PubMed ID: 22995332
[TBL] [Abstract][Full Text] [Related]
19. Reciprocal cross-regulation between RNF41 and USP8 controls cytokine receptor sorting and processing.
De Ceuninck L; Wauman J; Masschaele D; Peelman F; Tavernier J
J Cell Sci; 2013 Aug; 126(Pt 16):3770-81. PubMed ID: 23750007
[TBL] [Abstract][Full Text] [Related]
20. Inhibiting USP8 overcomes hepatocellular carcinoma resistance via suppressing receptor tyrosine kinases.
Zhu Y; Xu J; Hu W; Wang F; Zhou Y; Gong W; Xu W
Aging (Albany NY); 2021 Jun; 13(11):14999-15012. PubMed ID: 34081623
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
